Scientific Presentations
2023
VRDN-001, a Full Antagonist Antibody to IGF-1R: Proof-of-Concept Results in Chronic TED
Annual Meeting of The European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS)
September 2023
In Vitro Pharmacology and Phase 1/2 Results of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED)
Annual Meeting of The European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS)
September 2023
VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor: In Vitro Pharmacology and Phase 1/2 Results in Patients With Thyroid Eye Disease (TED)
Annual Meeting of the European Thyroid Association (ETA 2023)
September 2023
Preclinical Pharmacokinetics and Clinical Exposure Prediction for VRDN-003, a Next-Generation Half-life Extended Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED)
Annual Meeting of the European Thyroid Association (ETA 2023)
September 2023
VRDN 001, a Full Antagonist Antibody to IGF 1 Receptor in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab
Annual Meeting of the Endocrine Society (ENDO 2023)
June 2023
Durability of Treatment Response With VRDN 001, a Full Antagonist Antibody to IGF 1 Receptor, in Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
Annual Meeting of the Endocrine Society (ENDO 2023)
June 2023
Durability of Treatment Response With VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
Annual Meeting of the Endocrine Society (ENDO 2023)
June 2023
VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED): Pharmacodynamic Responses in Healthy Volunteers and Patients with Active TED
Annual Meeting of the Endocrine Society (ENDO 2023)
June 2023
Phase 1/2 Trial of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor, in Patients with Thyroid Eye Disease (TED)
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023
VRDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic/Pharmacodynamic (PK/PD) Results in Healthy Volunteers
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023
Preclinical Pharmacokinetics and Bioavailability of VRDN-002, a Next-Generation Half-Life Extended Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED)
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023
Preclinical Pharmacokinetics of VRDN-003, a Next-Generation Half-life Extended Antibody to the IGF-1 Receptor for Thyroid Eye Disease
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023
Design and Preclinical Characterization of VRDN-003, a Next Generation, Half-life Extended Antibody to IGF-1R in Development for Thyroid Eye Disease (TED)
Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 2023
VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Phase 1/2 Clinical Study in Patients
North American Neuro-Ophthalmology Society 2023 Annual Meeting
March 2023
THRIVE Phase 3 Trial of VRDN-001: A Full Antagonist Antibody to the IGF-1 Receptor for Thyroid Eye Disease (TED)
North American Neuro-Ophthalmology Society 2023 Annual Meeting
March 2023
VRDN-001, a Full Antagonist Antibody to IGF-1R in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab
North American Neuro-Ophthalmology Society 2023 Annual Meeting
March 2023
VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED): Interim Phase 1/2 Pharmacodynamic Results
North American Neuro-Ophthalmology Society 2023 Annual Meeting
March 2023
VRDN-002, a Novel Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Results of a Phase 1 Trial
North American Neuro-Ophthalmology Society 2023 Annual Meeting
March 2023
2022
VRDN-001, A Potent and Selective Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease (TED): Phase 1 Safety and Pharmacodynamic Results in Healthy Volunteers
American Thyroid Association (ATA) 2022 Annual Meeting
October 22, 2022
VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) for Thyroid Eye Disease (TED): Phase 1/2 Proof of Concept in Patients with TED
American Thyroid Association (ATA) 2022 Annual Meeting
October 21, 2022
VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab
American Thyroid Association (ATA) 2022 Annual Meeting
October 20, 2022
2021
Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody for the Treatment of Thyroid Eye Disease
American Thyroid Association (ATA) 2021 Annual Meeting
October 2, 2021
VRDN-002, A Second-Generation Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody for TED: Preclinical PK Profile and Clinical Promise
American Thyroid Association (ATA) 2021 Annual Meeting
September 30, 2021